Matrix Asset Advisors Inc. NY decreased its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 4.8% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 70,097 shares of the medical research company’s stock after selling 3,545 shares during the period. Thermo Fisher Scientific accounts for about 1.9% of Matrix Asset Advisors Inc. NY’s holdings, making the stock its 24th largest position. Matrix Asset Advisors Inc. NY’s holdings in Thermo Fisher Scientific were worth $10,767,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently bought and sold shares of TMO. Independent Portfolio Consultants Inc. boosted its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the last quarter. Sharkey Howes & Javer boosted its position in Thermo Fisher Scientific by 1.0% in the first quarter. Sharkey Howes & Javer now owns 733 shares of the medical research company’s stock valued at $113,000 after buying an additional 7 shares during the last quarter. Advantage Investment Management LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $125,000. Penserra Capital Management LLC boosted its position in Thermo Fisher Scientific by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,150 shares of the medical research company’s stock valued at $176,000 after buying an additional 100 shares during the last quarter. Finally, South Texas Money Management Ltd. bought a new position in Thermo Fisher Scientific during the first quarter valued at $202,000. 87.05% of the stock is owned by institutional investors.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 175.97 on Friday. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $182.87. The company has a market cap of $68.84 billion, a price-to-earnings ratio of 32.10 and a beta of 1.06. The stock has a 50 day moving average of $176.80 and a 200 day moving average of $163.47.
Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The firm had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. During the same quarter in the prior year, the firm posted $2.03 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 10.2% on a year-over-year basis. Equities research analysts predict that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.
TMO has been the subject of several research analyst reports. Deutsche Bank AG raised their target price on shares of Thermo Fisher Scientific from $163.00 to $188.00 and gave the company a “buy” rating in a research note on Friday, April 28th. BTIG Research raised their target price on shares of Thermo Fisher Scientific from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Friday, April 28th. Barclays PLC set a $175.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 26th. Leerink Swann set a $187.00 price objective on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Thursday, April 27th. Finally, Bank of America Corporation increased their price objective on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, May 9th. One research analyst has rated the stock with a hold rating, fifteen have assigned a buy rating and two have assigned a strong buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and an average price target of $188.69.
In related news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the completion of the transaction, the chief executive officer now directly owns 269,279 shares in the company, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. Insiders sold 27,188 shares of company stock valued at $4,702,223 in the last three months. 0.49% of the stock is currently owned by insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.
